Acquiring Company
AbbVie Inc.
Acquired Company
Revolution Medicines
North ChicagoRedwood CityManufacturingBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalDescription
AbbVie is reportedly concluding acquisition talks with Revolution Medicines Inc., following a significant stock price surge of approximately 30%. The negotiations are expected to have a positive impact on shareholders, given Revolution Medicines' current valuation of around $16 billion. The acquisition talks are attracting attention from other pharmaceutical companies, including Merck, indicating high interest in Revolution Medicines' innovative offerings.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Revolution Medicines?
Revolution Medicines was acquired by AbbVie Inc., based in North Chicago. The deal was reported on January 9, 2026. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Revolution Medicines?
AbbVie Inc.'s acquisition of Revolution Medicines was reported on January 9, 2026. AbbVie is reportedly concluding acquisition talks with Revolution Medicines Inc., following a significant stock price surge of approximately 30%. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Revolution Medicines do?
Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. It is publicly traded (RVMD), operating in Biotechnology, and is based in Redwood City.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.